Kennedy Resigns As Indirect Costs Controversy Mounts

WASHINGTON: On July 29, as Donald Kennedy announced his resignation as president of Stanford University, research institutions throughout the United States were rushing to meet a 5 P.M. deadline to comment on changes in the rules governing how much they can charge for the indirect costs of doing federally funded research. Although the timing was a coincidence, the simultaneity of the activities symbolized Kennedy's inability to quell, through personal response, the indirect costs controversy t

Written byJeffrey Mervis
| 7 min read

Register for free to listen to this article
Listen with Speechify
0:00
7:00
Share

Although the timing was a coincidence, the simultaneity of the activities symbolized Kennedy's inability to quell, through personal response, the indirect costs controversy that has plagued the U.S. academic world for the past several months a controversy that Kennedy and his institution principally precipitated.

His peers in academe note that failure even as they give expression to their sympathy. "The events of the past year are a sorry climax to a brilliant career," says Richard Atkinson, chancellor of the University of California, San Diego. In the opinion of Donald Langenberg, chancellor of the University of Maryland, "it's terribly unfortunate that a concatenation of events, including indirect costs, led him to conclude that it would be best to step down." And Derek Bok, who recently retired after 20 years as president of Harvard University, issued a statement saying that "the difficult events of the last year should not obscure the great ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies